32 results about "Guanosine triphosphate" patented technology

The invention relates to a reagent for detection of biological activity of glucagon-like peptide-1 (GLP-1). Each 100 microliters of the reagent mainly comprises 20 micrograms of a gene recombinant GLP-1 acceptor, a dipeptidyl peptidase-4 inhibitor of which the weight is 1% of the weight of a blood plasma sample, 480 micrograms of triphosadenine, 10 micrograms of guanosine triphosphate, 0.5 milligrams of 3-isobutyl-1-methylxanthine and 100 microliters of a membrane reaction solution. The GLP-1 acceptor is obtained by genetic recombination, is convenient for purification and reduces batch difference of the reagent. The GLP-1 acceptor is used as a probe for capturing GLP-1 so that detection sensitivity is improved, biological activity can be directly determined, sensitivity is high, and practicality is strong.

The invention discloses a small G-protein Rop family protein, a coding gene and an application of the hevea brasiliensis latex small G-protein Rop family protein. The protein is a protein having one of the following amino acid residue sequences: 1) protein composed of an amino acid residue sequence of SEQ ID No.1 in a sequence table; 2) SEQ ID No.1 derived protein obtained by subjecting the amino acid residue sequence of SEQ ID No.1 in the sequence table to substitution and / or deletion and / or addition of one or more amino acid residues and having GTP (guanosine triphosphate) binding function. The protein has GTP binding activity, plays a certain role in basic disease-resistant mechanism and stress resistance of plants, and has the characteristics of control for secondary xylem and phloem development of woods. The protein can improve the resistance of transgenic crop or woods against adverse situation, so as to improve the yield.

The invention provides methods to inhibit the replication of a flavivirus, methods of inhibiting the guanosine triphosphate (GTP)-binding and guanylyltransferase activity of a flavivirus RNA capping enzyme, and methods of treating a subject infected with a flavivirus. The methods can include contacting a flavivirus with an effective amount of a thioxothiazolidine compound described herein, or a derivative thereof, such as a compound of Formula (I).

The invention discloses a method for testing BNP (Brain Natriuretic Peptide) activity by using a GCA stable transfection cell line and establishes a novel BNP bioactivity testing method. GCA which is a main acceptor of BNP is an adenylate cyclase precursor and can catalyze GTP (guanosine triphosphate) to generate cGMP after being activated by the BNP and then exerts a biological effect. Wield 293 cell has low GCA expression level and low reactivity to BNP. In the method disclosed by the invention, a stable cell line 293GCAC3 with BNP acceptor (GCA) overexpression level is structured by transgenosis, the content change of cGMP secreted into cell supernatant by the 293GCAC3 stimulated by the BNP is detected to quantify the activity of the BNP. The method comprises the following specific testing steps of: laying cells on a 96-pore plate and culturing for 16-18 hours; adding the BNP for stimulating for 90 minutes; and sucking cell supernatant and detecting the content of cGMP with competitive ELISA (enzyme-linked immuno sorbent assay). The method is simple to operate, has sensitive response and small variability and is significant for the quality control and clinical application of the BNP.

The invention belongs to the technical field of scale production of candidate medicines for treating glucose-lipid metabolism disorder diseases. In order to solve the problems that existing S-AMP is difficultly produced, the price of the S-AMP is expensive, and raw material sources of the druggability of the S-AMP is difficulty ensured, the invention provides a preparation method of adenylosuccinic acid or adenylosuccinate. PhAdSS of which the N terminal is provided with an His-tag sequence is expressed by utilizing a pET-28-a carrier; with the PhAdSS as a catalyst, inosinic acid IMP, L-aspartic acid and guanosine triphosphate (GTP) are catalyzed and subjected to reaction to synthesize S-AMP; after the reaction is carried out, components in a product are analyzed by adopting silica gel thin-layer chromatography, and separation and purification on the S-AMP are carried out by adopting silica gel coluumn chromatography. The content of the s-AMP in a synthetic product is 61 percent, and arecycling ratio is about 20 percent. A preparation process is simple, the cost is low, and a basis is laid for building an industrialized S-AMP synthetic process; monopoly sale on S-AMP by foreign sellers is expected to be broken through, and the S-AMP druggability research cost can be greatly reduced.